Loading
Life sciences · Phase 1 Trial
ClinicalTrials.gov · October 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06997029). This is a study registration, not published results. Lead sponsor: Bristol-Myers Squibb. Recruitment status: RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 234 participants (ESTIMATED). Conditions: Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer. Interventions: DRUG: BMS-986500; DRUG: Palbociclib; DRUG: Fulvestrant. Primary outcome measures: Number of Participants With Dose Limiting Toxicities (DLTs) , Up to Day 28 From Last Dose; Number of Participants With Adverse Events (AEs) , Up to Day 28 From Last Dose; Number of Participants With Serious Adverse Events (SAEs) , Up to Day 28 From Last Dose; Number of Participants With AEs Leading to Discontinuation , Up to Day 28 From Last Dose; Number of Participants With TEAEs Leading to Death , Up to Day 28 From Last Dose. Brief summary: The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.